Posters

Retrospective analyses of capsular block formation in patients with cataract and pseudoexfoliation syndrome

Poster Details

First Author: N. Lutsenko UKRAINE

Co Author(s):    O. Isakova   O. Rudycheva                 

Abstract Details

Purpose:

to study the frequency and reasons of capsular block formation during cataract surgery or in postoperative period in patients with cataract and pseudoexfoliation syndrome PXE

Setting:

State Institution 'Zaporizhya Medical Academy of Postgraduate Education Ministry of Public Health of Ukraine'

Methods:

Retrospectively were analyzed 320 patients (400 eyes) with cataract and PXF. All patients were operated by one surgeon. The age of the patients was between 60 and 89 years. Pupillary diameter after dilatation was measured and graded as poor (2-4 mm), moderate (4-5 mm) and good (5.5-6.5 mm or more). The viscoelastic materials used included sodium hyaluronate 3%-chondroitin sulfate 4% (Viscoat®, Alcon) and 1.4% sodium hyaluronate (Hyaral, Ukraine ). The continuous curvilinear capsulorhexis (CCR) size ranged from 4.5 to 5.5 mm. The IOL was implanted into the capsular bag.

Results:

Intraoperative CBS (anterior chamber shallowing at the time of hydrodissection, iris prolaps) occurred at 4 eyes (1 %), early postoperative block (anterior chamber shallowing, anterior displacement of the IOL, unexpected myopic over-refraction) - at 9 eyes (2,2 %). All cases of intraoperative CBS occurred in the patients with poor or moderate pupilary dilatation. Postoperative CBS were resolved spontaneous in 2 weeks at 5 patients with the use of hypotensive therapy. YAG laser capsulotomy ( antelrior or posterior) was performed at 4 patients. In all cases of CBS IOL implantation was made in the presence of a small (4.0–4.5 mm) anterior CCC.

Conclusions:

CBS developed in patients with rigid pupil, depends on the accumulation of a liquefied substance inside the capsular bag, due to capsulorhexis block by the lens nucleus (during phacoemulsification) or posterior chamber IOL( in postoperative period).

Financial Disclosure:

NONE